Agilon Health (NYSE:AGL) Rating Lowered to Underweight at JPMorgan Chase & Co.

Agilon Health (NYSE:AGL) was downgraded by stock analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a report issued on Monday. They presently have a $21.00 price objective on the stock. JPMorgan Chase & Co.‘s price target indicates a potential downside of 29.01% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. Benchmark lifted their target price on Agilon Health to $13.00 and gave the stock a “buy” rating in a report on Thursday, April 2nd. Wells Fargo & Company lifted their target price on Agilon Health from $25.00 to $37.50 and gave the stock an “overweight” rating in a report on Friday, February 27th. Deutsche Bank Aktiengesellschaft set a $33.00 target price on Agilon Health and gave the stock a “hold” rating in a report on Thursday, April 9th. Citigroup dropped their target price on Agilon Health from $21.25 to $18.75 and set a “neutral” rating for the company in a report on Tuesday, March 3rd. Finally, Barclays decreased their price target on Agilon Health from $25.00 to $12.50 and set an “underweight” rating for the company in a research note on Friday, February 27th. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $38.48.

Agilon Health Price Performance

Shares of Agilon Health stock opened at $29.58 on Monday. The stock has a market cap of $492.84 million, a price-to-earnings ratio of -1.25 and a beta of 2.29. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.02 and a current ratio of 1.02. The stock has a 50 day moving average price of $17.16 and a 200-day moving average price of $17.96. Agilon Health has a one year low of $7.48 and a one year high of $119.50.

Agilon Health (NYSE:AGL) last announced its earnings results on Wednesday, February 25th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.19). The company had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.46 billion. Agilon Health had a negative return on equity of 120.82% and a negative net margin of 6.60%. Equities analysts expect that Agilon Health will post -6.35 EPS for the current year.

Institutional Investors Weigh In On Agilon Health

Institutional investors and hedge funds have recently modified their holdings of the business. Wealthcare Advisory Partners LLC bought a new stake in shares of Agilon Health during the 3rd quarter worth approximately $26,000. LPL Financial LLC lifted its stake in shares of Agilon Health by 213.4% during the 4th quarter. LPL Financial LLC now owns 44,055 shares of the company’s stock worth $30,000 after acquiring an additional 30,000 shares during the last quarter. Krilogy Financial LLC bought a new stake in shares of Agilon Health during the 4th quarter worth approximately $34,000. CIBC Bancorp USA Inc. bought a new stake in shares of Agilon Health during the 3rd quarter worth approximately $34,000. Finally, Merit Financial Group LLC bought a new stake in shares of Agilon Health during the 4th quarter worth approximately $35,000.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.